



SMERA RATINGS LIMITED

# Richcore Lifesciences Private Limited (RLPL)

*Rating  
Rationale*

**April 06, 2016**

Facilities	Amount (Rs. Crore)	Ratings
Cash Credit	2.00	SMERA B-/Stable (Assigned)
Term Loan	5.50	SMERA B-/ Stable (Assigned)
Letter of Credit	0.50	SMERA A4 (Assigned)

SMERA has assigned ratings of **SMERA B- (read as SMERA B minus)** and **SMERA A4 (read as SMERA A four)** to the Rs.8.00 crore bank facilities of Richcore Lifesciences Private Limited (RLPL). The outlook is '**Stable**'. For arriving at the ratings, SMERA has consolidated the business and financial risk profiles of two entities of the Richcore Group viz. RLPL and Richcore Enzymes Private Limited (REPL). The consolidation is in view of the common management and business synergies between the entities. The rating is constrained by Richcore's modest scale of operations, losses resulting in deteriorating net worth, negative cash flow from operations and working capital-intensive operations. However, these risks are partially offset by fund infusion in FY2015-16, reputed clientele and experienced management.

## **Outlook: Stable**

SMERA believes that the group will maintain a stable business profile over the medium term on account of its reputed clientele and experienced management. The outlook maybe revised to 'Positive' in case of increasing profitability and effective working capital management. Conversely, the outlook may be revised to 'Negative' with stretch in the working capital management or deterioration in the financial risk profile.

## **Rating Sensitivity Factors**

- Scaling up of operations with healthy profitability
- Effective working capital management
- Future capex plan and its funding

## **About the Company**

Incorporated in 2005, RLPL is a Karnataka-based company engaged in developing enzyme solutions for cleantech and biopharma applications. The company plans to acquire its group entity, REPL engaged in processing of enzymes used in the pharma industry.

The company is managed by a lead of experts with Mr. Subramani Ramachandrappa as the Managing Director and Chief Executive Officer.

**Disclaimer:** A SMERA rating does not constitute an audit of the rated entity and should not be treated as a recommendation or opinion that is intended to substitute for a financial adviser's or investor's independent assessment of whether to buy, sell or hold any security. SMERA ratings are based on the data and information provided by the issuer and obtained from other reliable sources. Although reasonable care has been taken to ensure that the data and information is true, SMERA, in particular, makes no representation or warranty, expressed or implied with respect to the adequacy, accuracy or completeness of the information relied upon. SMERA is not responsible for any errors or omissions and especially states that it has no financial liability whatsoever for any direct, indirect or consequential loss of any kind arising from the use of its ratings. SMERA ratings are subject to a process of surveillance which may lead to a revision in ratings as and when the circumstances so warrant. Please visit our website ([www.smera.in](http://www.smera.in)) for the latest information on any instrument rated by SMERA.



SMERA RATINGS LIMITED

# Richcore Lifesciences Private Limited (RLPL)

*Rating  
Rationale*

For FY 2014-15, the Richcore Group reported net loss of Rs.12.77 crore on total income of Rs.8.95 crore.

**Contact List:**

Media/Business Development	Analytical Contact	Rating Desk
Suman M National Sales Head – Emerging Corporate Group Tel: +91-22-6714 1151 Cell: +91- 98923 06888 Email: <a href="mailto:suman.m@smera.in">suman.m@smera.in</a> Web: <a href="http://www.smera.in">www.smera.in</a>	Mohit Jain Vice President – Rating Operations Tel: +91-22-6714 1105 Email: <a href="mailto:mohit.jain@smera.in">mohit.jain@smera.in</a>	Tel: +91-22-6714 1184 Email: <a href="mailto:ratingdesk@smera.in">ratingdesk@smera.in</a>

**Disclaimer:** A SMERA rating does not constitute an audit of the rated entity and should not be treated as a recommendation or opinion that is intended to substitute for a financial adviser's or investor's independent assessment of whether to buy, sell or hold any security. SMERA ratings are based on the data and information provided by the issuer and obtained from other reliable sources. Although reasonable care has been taken to ensure that the data and information is true, SMERA, in particular, makes no representation or warranty, expressed or implied with respect to the adequacy, accuracy or completeness of the information relied upon. SMERA is not responsible for any errors or omissions and especially states that it has no financial liability whatsoever for any direct, indirect or consequential loss of any kind arising from the use of its ratings. SMERA ratings are subject to a process of surveillance which may lead to a revision in ratings as and when the circumstances so warrant. Please visit our website ([www.smera.in](http://www.smera.in)) for the latest information on any instrument rated by SMERA.